SAFLI-R21-10 is an ancillary study conducted within the framework of the IMVACS project and designed to compare the safety, reactogenicity, and humoral immunogenicity of the 10-dose formulation of R-21/Matrix-M with 2-Phenoxyethanol preservative vs the safety, reactogenicity, and humoral immunogenicity of the 2-dose formulation of R21/Matrix-M vaccine.

📅 29th July 2025📍 Kola Cscom, Dioïla District, Mali👥 Participants enrolled in the IMVACS study to date: 23,227 The first diary page that brings to life the daily efforts of our field team and highlights the ongoing journey of the IMVACS trial.

The Liverpool School of Tropical Medicine (LSTM) is excited to invite applications for two academic positions to support ongoing research on vaccine implementation in Burkina Faso, Mali, and Chad.Successful candidates will join the IMVACS project and contribute to other vaccine-related research initiatives. 🔍 Open Positions:1. Lecturer / Senior Lecturer in Health Economics (Vaccines): to contribute…

On the 18th anniversary of World Malaria Day, the IMVACS Consortium is extremely pleased to announce the launch of another significant and exciting research initiative in the fight against malaria: the CoSAV-R21 trial. In June 2025, Epicentre/MSF in collaboration with other IMVACS partners, the Liverpool School of Tropical Medicine (LSTM), and the Centre National de…

Exciting update about IMVACS project As part of Work Package 6 on formative research, acceptability, feasibility, and cost-effectiveness, the IMVACS Consortium successfully convened a two-day stakeholders’ workshop on 7th and 8th March, in Dioïla, Mali.

The Data Safety Monitoring Board is officially in place! 📣 The IMVACS team is glad to announce that its initial organizational Data Safety Monitoring Board meeting was successfully held on 31st March.

The project Kick-off Meeting was held in Abidjan, Côte d’Ivoire, on 11th and 12th February.